Brazilian health regulator Anvisa has approved new phase 2 and 3 clinical trials for a potential vaccine developed by Chinese firm Sichuan Clover Biopharmaceuticals. The decision was made on Friday and published today.
The study will use up to 30,000 volunteers from countries in Latin America, Europe, Asia, and Africa. Roughly 12,100 participants will come from Brazil, specifically from the states of Rio Grande do Sul, Rio de Janeiro, and Rio Grande do Norte.
This will be the sixth Covid-19 vaccine clinical trial approved in Brazil — after those of AstraZeneca, Sinovac, Pfizer, Johnson & Johnson, and Medicago-GSK.
Search
